Menu
Essential HTN. Reduction of the risk of MI, stroke or death in patients ≥55 yr at high risk developing major CV events who are unable to take ACE inhibitors. High risk CV events including evidence of CAD, peripheral arterial disease, stroke, transient ischemic attack or diabetes w/ evidence of end-organ damage. Additional treatment to antihypertensive, antiplatelet or lipid-lowering therapy.
White oblong tablets of 4.6 mm engraved with the code number ’52H’ on one side and the company logo on the other side.
Essential HTN. Reduction of the risk of MI, stroke or death in patients ≥55 yr at high risk developing major CV events who are unable to take ACE inhibitors. High risk CV events including evidence of CAD, peripheral arterial disease, stroke, transient ischemic attack or diabetes w/ evidence of end-organ damage. Additional treatment to antihypertensive, antiplatelet or lipid-lowering therapy.
| Weight | 0.2 kg |
|---|
